Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP versus GEM-P for first-line T-cell lymphoma
2011-004146-18Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, cisplatin, methylprednisolone, cyclophosphamide, doxorubicin and 2 more in T-cell lymphoma (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Metabolic complete response rate. Status: unknown.
02
Drugs
gemcitabinecisplatinmethylprednisolonecyclophosphamidedoxorubicin
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on 2011-004146-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004146-18.